Coronavirus Diaries: A Covid scientist on the hunt for a cure, and a GP on what doctors need to learn Financial Times
Coronavirus Diaries: A Covid scientist on the hunt for a cure, and a GP on what doctors need to learn Financial Times
The Food and Drug Administration (FDA) has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of coronavirus disease 2019 (COVID-19). The multicenter, randomized, blinded, placebo-controlled SUCCESS (Systemic Umbilical Cord Cells to Ease Severe Syndrome) study will assess the efficacy and safety of umbilical cord mesenchymal stem cells provided by RESTEM, a cell-based therapeutics company, in hospitalized patients with severe COVID-19 (N=60). RESTEMs cells are grown from umbilical cord tissue through a proprietary process that rapidly replicates millions of doses.
The year of 2020 has been unlike any other year. Since January, the global COVID-19 pandemic has impacted every aspect of our lives affecting our health, our economy and our livelihoods
A contemporary development prediction report titled GlobalMesenchymal Stem CellsMarket Growth 2020-2025 constitutes a comprehensive analysis of the global market which underlines market components, probability features, and product particulars, and technological advancements influencing the global Mesenchymal Stem Cells market development. The market to begin with establishes the basis of the markets: definitions, categorizations, offerings, and market rundown, product particulars, producing procedures, cost structures, and raw materials. The report scrutinizes market size and predictions by product, area, and market challenging condition among the traders and company portrait apart from market price analysis and value chain.
CRANFORD, N.J., May 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that data on NoveCite MSCs will be presented this week at the American Society of Gene and Cell therapy (ASGCT) annual meeting
Technology across the world is improving and innovatingwith time. Over the years, man-managed labor has almost finished from themarket and more and more technological and scientific gadgets are taking placemaking human labor more effective, efficient, and precise. Medical science has also taken a lot of advantage fromthis scientific advancement therefore, we can say that doctors are making fulluse of science and technology and the world of medicine has evolved quiterapidly.
Korean researchers have found a signal transduction system that modulates the treatment of mesenchymal stem cells and immune control functions, opening the way for treating graft-versus-host disease treatment.
The SARS-CoV2 pandemic has ignited a massive effort across the globe, led by medical researchers and biotech companies, to come up with therapies that can help patients and bring an end to the pandemic. Vaccines, antibodies, immunity and convalescent plasma have all become common medical terms used in households across the country. However, what we haven't heard much about in the main stream media may be one of the most promising therapies to get COVID-19 patients off a ventilator.
Alessandra de Oliveira Pinheiro,1 Valria M Lara,1 Aline F Souza,1 Juliana B Casals,2 Fabiana F Bressan,1 Paulo Fantinato Neto,1 Vanessa C Oliveira,1 Daniele S Martins,1 Carlos E Ambrosio1 1Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of So Paulo, Pirassununga, So Paulo, Brazil; 2Private Veterinary Practice, Pirassununga, So Paulo, Brazil Correspondence: Carlos E AmbrosioDepartment of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of So Paulo, FZEA- Av. Duque de Caxias Norte, 225, ZMV, Pirassununga 13635-900, So Paulo, BrazilTel +55 19 3565-4113 Email ceambrosio@usp.br Purpose: Amniotic membrane stem cells have a high capacity of proliferation, cell expansion, and plasticity, as well as immunomodulatory properties that contribute to maternal-fetal tolerance. Owing to the lack of research on human amniotic membrane at different gestational stages, the canine model is considered ideal because of its genetic and physiological similarities
Alexanderstock23 / Shutterstock The U.S. Food and Drug Administration (FDA) announced on Tuesday that it has approved dapagliflozin, also known under the brand name Farxiga, for the treatment of heart failure in adults with reduced ejection fraction. The drug can potentially reduce the risk of cardiovascular death and hospitalization for heart failure.
Recent Comments